Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 3781 AL 3795

Impact of gene mutation in the development of Parkinson's disease

Selvaraj S, Piramanayagam S.

Genes Dis. 2019 Feb 27;6(2):120-128. doi: 10.1016/j.gendis.2019.01.004. eCollection 2019 Jun.

Adaptive deep brain stimulation as advanced Parkinson's disease treatment (ADAPT study): protocol for a pseudo-randomised clinical study

Piña-Fuentes D, Beudel M, Little S, Brown P, Oterdoom DLM, van Dijk JMC.

BMJ Open. 2019 Jun 14;9(6):e029652. doi: 10.1136/bmjopen-2019-029652.

Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054

Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, Makh S, Aldred J, Goodman I, Pepinsky B, Liu Y, Graham D, Weihofen A, Cedarbaum JM.

Mov Disord. 2019 Aug;34(8):1154-1163. doi: 10.1002/mds.27738. Epub 2019 Jun 17.

Changing views of the pathophysiology of Parkinsonism

Wichmann T.

Mov Disord. 2019 Aug;34(8):1130-1143. doi: 10.1002/mds.27741. Epub 2019 Jun 19.

STXBP1 encephalopathy: Connecting neurodevelopmental disorders with α-synucleinopathies?

Lanoue V, Chai YJ, Brouillet JZ, Weckhuysen S, Palmer EE, Collins BM, Meunier FA.

Neurology. 2019 Jul 16;93(3):114-123. doi: 10.1212/WNL.0000000000007786. Epub 2019 Jun 20.

A Case of Carbon Monoxide-Induced Delayed Neurological Sequelae Successfully Treated with Hyperbaric Oxygen Therapy, N-Acetylcysteine, and Glucocorticoids: Clinical and Neuroimaging Follow-Up

Spina V, Tomaiuolo F, Celli L, Bonfiglio L, Cecchetti L, Carboncini MC.

Case Rep Neurol Med. 2019 May 15;2019:9360542. doi: 10.1155/2019/9360542. eCollection 2019.

Gene-targeting approaches for movement disorders: recent advances

Kaplitt MG.

Curr Opin Neurol. 2019 Aug;32(4):566-570. doi: 10.1097/WCO.0000000000000719.

Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference

Stacy M, Sajatovic M, Kane JM, Cutler AJ, Liang GS, O'Brien CF, Correll CU.

Mov Disord. 2019 Aug;34(8):1203-1209. doi: 10.1002/mds.27769. Epub 2019 Jun 24.

Treatment of psychiatric disturbances in hypokinetic movement disorders

Berardelli I, Belvisi D, Pasquini M, Fabbrini A, Petrini F, Fabbrini G.

Expert Rev Neurother. 2019 Oct;19(10):965-981. doi: 10.1080/14737175.2019.1636648. Epub 2019 Jul 2.

Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease

Vila M.

Mov Disord. 2019 Oct;34(10):1440-1451. doi: 10.1002/mds.27776. Epub 2019 Jun 28.

Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond

Bayne AN, Trempe JF.

Cell Mol Life Sci. 2019 Dec;76(23):4589-4611. doi: 10.1007/s00018-019-03203-4. Epub 2019 Jun 28.

Recent developments in drug-induced movement disorders: a mixed picture

Factor SA, Burkhard PR, Caroff S, Friedman JH, Marras C, Tinazzi M, Comella CL.

Lancet Neurol. 2019 Sep;18(9):880-890. doi: 10.1016/S1474-4422(19)30152-8. Epub 2019 Jul 3.

One decade ago, one decade ahead in progressive supranuclear palsy

Stamelou M, Giagkou N, Höglinger GU.

Mov Disord. 2019 Sep;34(9):1284-1293. doi: 10.1002/mds.27788. Epub 2019 Jul 8.

The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease

Moosa S, Martínez-Fernández R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS.

Mov Disord. 2019 Sep;34(9):1243-1251. doi: 10.1002/mds.27779. Epub 2019 Jul 10.

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE.

J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1317-1323. doi: 10.1136/jnnp-2018-319918. Epub 2019 Jul 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias